Termen/ afkortingen Flashcards
1 - Introduction
GLP
Good laboratory practice
1 - Introduction
GCP
Good clinical practice
1 - Introduction
GMP
Good manufacturing practice
1 - Introduction
CTD
European Clinical Trials Directive
1 - Introduction
CTR
European Clinical Trials Regulation
1 - Introduction
NCE
New Chemical Entity
1 - Introduction
NME
New Molecular Entity
1 - Introduction
NBE
New Biological Entity
2 - Drug discovery
MTX
Methotrexaat
3 - Drug discovery
SAR
structure activity relationship
4 - Farmaceutical development
PAMPA
parallel artificial membrane permeability assay
4 - Pharmaceutical development
API
Active pharmaceutical ingredient
Drug = API + excipients
4 - Pharmaceutical development
HTS
High throughput screening
4 - Pharmaceutical development
BCS
Biofarmaceutisch classificatiesysteem
4 - Pharmaceutical development
FaSSIF
Fasted state stimulated intestinal fluid
4 - Pharmaceutical development
FeSSIF
Fed state stimulated intestinal fluid
4 - Pharmaceutical development
HPMC
Hydroxypropylmethylcellulose
4 - Pharmaceutical development
PF
Polariteit factor
4 - Pharmaceutical development
IV
Intraveneus
4 - Pharmaceutical development
IM
Intramusculair
4 - Pharmaceutical development
SC
Subcutaan
4 - Pharmaceutical development
TTS
Transdermaal therapeutisch systeem
4 - Pharmaceutical development
MEC
Minimale effectieve concentratie
4 - Pharmaceutical development
IUD
Intra uterine device
4 - Pharmaceutical development
IA
Intra-arteriaal of intra-articulair
4 - Pharmaceutical development
IT
Intrathecal
4 - Pharmaceutical development
IC
Intracardiaal
4 - Pharmaceutical development
MPS
Mononuclear fagocyt systeem
4 - Pharmaceutical development
EPR
Enhanced permeability and retention
4 - Pharmaceutical development
MLV
Multilamellar vesicles
4 - Pharmaceutical development
SUV
Small unilamellar vesicles
4 - Pharmaceutical development
LUV
Large unilamellar vesicles
5 - Clinical drug development
IB
Investigator’s brochure
5 - Clinical drug development
IND
Investigational New Drug application
Gelijkaardig aan CTA, clinical trial application (EU)
5 - Clinical drug development
DART
Developmental and reproductive toxicity
5 - Clinical drug developmental
NOEL
No Observed Effect Level
5 - Clinical drug development
NOAEL
No Observed Adverse Effect Level
5 - Clinical drug development
MRSD
Maximal Recommended Starting Dose
5 - Clinical drug development
HED
Human equivalent dose
5 - Clinical drug development
MABEL
Minimal anticipated biological effect level
5 - Clinical drug development
PAD
Pharmaceutical active dosis
5 - Clinical drug development
PBPK
Physiology based pharmacokinetics
5 - Clinical drug development
FIH
First in human
5 - Clinical drug development
FIM
First in man
5 - Clinical drug development
MTD
Maximale tolereerbare dosis
5 - Clinical drug development
ATD
Anticipated therapeutic dose
5 - Clinical drug development
SAD
Single ascending dose
5 - Clinical drug development
MAD
Multiple ascending dose
5 - Clinical drug development
AUC
Area under the curve
6 - Clinical drug development
PoP
Proof of Principle
6 - Clinical drug development
PoC
Proof of Concept
6 - Clinical drug development
ADA
Anti drug antibodies
7 - Clinical drug development
NDA
New Drug Application
7 - Clinical drug development
IMP
Investigational medical products
7 - Clinical drug development
RCT
Randomized controlled trial
7 - Clincal drug development
SoC
Standard of Care
7 - Clinical drug development
IVRS
Interactive Voice Response System
Computerized ranomization
7 - Clinical drug development
MA
Market Authorisation
8 - Clinical drug development
eCTA
Exploratory clinical trial application
Microdosing or phase 0
8 - Clinical drug development
eIND
Exploratory investigational new drug
In de US de term voor eCTA
8 - Clinical drug development
PET
Positron emission tomography
8 - Clincial drug development
AMS
Accelerator mass spectrometry